TMED9 Expression Level as a Biomarker of Epithelial Ovarian Cancer Progression and Prognosis.

Gwan Hee HanHee YunJoon-Yong ChungJae-Hoon KimHanbyoul Cho

Published in: Cancer genomics & proteomics (2022)

Overall, our results support the use of TMED9 as a valuable prognostic biomarker and provide evidence for targeting of TMED9 as a novel strategy for EOC treatment.

Keyphrases

poor prognosis
binding protein
drug delivery
replacement therapy